Clinical trials: Histological Response
Anal Cancer, Cervical Cancer
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in treating patients…
- Conditions
- Anal Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00019110
- Testing
- human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide
- Where
- 6 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
The purpose of this study is to determine the efficacy and toxicity profile of Pomalidomide and Dexamethasone in relapsed or refractory Multiple Myeloma patients with deletion 17p or translocation (4;14)
- Trial name
- IFM2010-02 (NCT01745640)
- Testing
- POMALIDOMIDE, Dexamethasone
- Where
- 20 sites in France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Lille
HRAS Gene Mutation, HNSCC
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN).
- Trial name
- AIM-HN/SEQ-HN (NCT03719690)
- Testing
- Tipifarnib, HRAS Detection Assay
- Where
- 102 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Kura Oncology, Inc.
Hepatocellular Carcinoma
Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with an incidence of 500 000 cases per year. HCC most commonly appears in a context of liver chronic disease (patient with chronic viral hepatitis…
- Trial name
- ETAFIRM (NCT02585687)
- Testing
- liver Perfusion MRI
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Hospices Civils de Lyon
Non Functioning Pancreatic Endocrine Tumor
Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors
Chromogranin A (CgA) is a glycoprotein with a molecular weight of 49 to 52 kDa produced by chromaffin cells of the adrenal medulla, enterochromaffin-like (ECL) cells, and endocrine cells of the stomach and pancreas, and it is the…
- Trial name
- CgA (NCT02759718)
- Testing
- Chromogranin A
- Volunteers
- 111 people
- Sponsor
- Asan Medical Center
Glioblastoma
Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma
This trial is a translational, open-label, monocentric prospective study of 80 patients aiming to study resistance mechanisms as well as biomarkers of resistance or sensitivity to TTFields.
- Trial name
- EXOFIELDS (NCT06222138)
- Testing
- The samples described below will be collected:
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Institut Claudius Regaud
Recurrent Glioma
Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas
Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2).
- Trial name
- NCT04216550
- Testing
- Apatinib
- Where
- China
- Volunteers
- 600 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients With Glioblastoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pentoxifylline and hydroxyurea may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00019058
- Testing
- chemotherapy, hydroxyurea, pentoxifylline
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Chronic Myeloid, Cancer
The EMPATHY Pilot Study
The proposed study, may significantly contribute to improve healthcare delivery in patients with Chronic Myeloid Leukemia (CML) treated with modern tyrosine kinase inhibitors (TKIs) in two ways.
- Trial name
- NCT04384848
- Testing
- EMPATHY Pilot
- Where
- 16 sites in United States, Italy
- Volunteers
- 94 people
- Sponsor
- Northwestern University
Dupuytren's Disease
Repurposing Anti-TNF for Treating Dupuytren's Disease
Dupuytren's disease is a very common condition, affecting 4% of the general UK and US population. It causes the fingers to curl irreversibly into the palm and can be extremely disabling.
- Trial name
- RIDD (NCT03180957)
- Testing
- Adalimumab, Saline
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 140 people
- Sponsor
- University of Oxford
Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
Study of Ipilimumab in the Immune System
Participants will be taking 3 mg/kg ipilimumab intravenously over a 90-minute period every 3 weeks for a total of four doses. Tumor-infiltrating lymphocytes (TILs)will be analyzed for functional characteristics.
- Trial name
- NCT01715077
- Testing
- Ipilimumab at 3 mg/kg dose
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Ovarian Cysts
Ovarian Clear Cell Adenocarcinoma Review
Clear cell carcinoma comprises 5-10% of surface epithelial ovarian cancers, and about 30-40% of the patients with clear cell carcinoma are diagnosed in the advanced stage.
- Trial name
- OCCA (NCT02129036)
- Volunteers
- 5 people
- Sponsor
- Cathay General Hospital
Breast Cancer
Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy
The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.
- Trial name
- SPAM (NCT00911911)
- Testing
- Blood sampling, BIOPSY, SURGERY
- Where
- 5 sites in France
- Volunteers
- 66 people
- Sponsor
- Centre Oscar Lambret
Head and Neck Squamous Cell Carcinoma (HNSCC)
Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET
This is a single-centre, non-randomized, two-stage design, proof-of-concept study evaluating the radiolabelled PARP inhibitor [18F]-olaparib als potential tracer for imaging of tumour PARP expression by PET.
- Trial name
- [18F]-olaparib (NCT06482307)
- Testing
- [18F]-olaparib PET scan
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Multiple Myeloma
Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma
The study involves the use of a targeted form of radiation, in addition to standard high dose chemotherapy and stem cell transplant for multiple myeloma.
- Trial name
- NCT01207765
- Testing
- indium-111-ibritumomab tiuxetan, 90Y Zevalin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Tufts Medical Center
Diffuse Large B Cell Lymphoma (DLBCL)
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).
- Trial name
- GRAIL (NCT06050694)
- Testing
- glofitamab
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Chronic Myeloid Leukemia
A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
This study is to evaluate efficacy and safety of Imatinib in two groups of patients; all patients should be diagnosed less than 3 months as chronic myeloid leukemia in a chronic phase.
- Trial name
- IDEAL (NCT02204722)
- Testing
- 600mg/day of Imatinib, 400mg/day of Imatinib
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Dong-A ST Co., Ltd.
Melanoma (Skin) Stage IV, Melanoma (Skin Cancer)
Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.
Previous research has shown that a higher fiber intake may have a beneficial effect on the intestinal health and improve the effectiveness of immunotherapy, but this is not certain.
- Conditions
- Melanoma (Skin) Stage IV, Melanoma (Skin Cancer), Melanoma Metastatic, Melanoma Advanced
- Trial name
- FIGURE-IM (NCT07686835)
- Testing
- Dried chicory roots
- Where
- 2 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Radboud University Medical Center
Head and Neck Squamous Cell Carcinoma
Anti-tumor Specific Immune Response in Head and Neck Cancers
The purpose is the description of anti-tumor immune responses in general and according to clinical stage and disease free survival (DFS: survival without recurrence (local or distant)) in patients with Head \& Neck Squamous Cell…
- Trial name
- CORISAT (NCT02881918)
- Testing
- Blood sample
- Where
- 6 sites in France
- Volunteers
- 154 people
- Sponsor
- Central Hospital, Nancy, France
Multiple Myeloma
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
There is no study hypothesis. The purpose of this study is to see if the Pneumococcal conjugate vaccine (PCV13), when administered before and early after an autologous peripheral stem cell transplant will induce an immune…
- Trial name
- PCV13 (NCT01852591)
- Testing
- PCV 13
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.